The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice
Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.
This activity is intended for hematology/oncology specialists and pharmacists.
The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).
Approximate Time to Complete: 30 minutes
Credit Available: Feb. 27, 2018 - Feb. 27, 2019
Developed through a partnership between SITC and Medscape.
- increase knowledge regarding the relevance of clinical trial design in patient selection and preferences in patients with advanced NSCLC
- Increase knowledge regarding clinical trial data on the use of immunotherapies in patients with advanced NSCLC
AMA PRA Category 1 Credit(s)™: 0.50
CEU: 0.50
ABIM MOC Part 2 Credits: 0.50